New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies…
Shook & Stone Opens Up “An Ideal Lawyer’s Portrait: Representation Matters” 2026 Scholarship
Marketing 1on1 Announces the Addition of Local Citations to Its Backlink Service Offerings
Think Business, Think Hong Kong strengthens Italy-Hong Kong ties and opens new path for Asian collaboration
FUTR Announces Q1 2026 Financial Results